$7.39 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$270 MillionTotal revenue in the last quarter.
$28.4 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$0.35Earnings per share is the amount of net income that is attributed to each single share outstanding.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
66.08xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$24.3 MillionEarnings before interest expenses and taxes in the last quarter.
0The number of full time employees.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in a fireside ...Business Wire, 2 months ago
– Results of phase 2 trial show CABOMETYX significantly improved progression-free survival versus current guideline-preferred therapy – – Data to be presented during the 2021… | February 13, 2021MarketScreener, 2 months ago
Exelixis, Inc. (NASDAQ: EXEL) today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NBusiness Wire, 2 months ago